New Haven, CT, United States

Time filter

Source Type

Patent
Stichting Vu Vumc and InteRNA Technologies | Date: 2015-06-19

Methods of diagnosing colorectal cancer and precursors thereof using miRNA biomarkers are disclosed, together with kits and devices for detecting the biomarkers, and uses of the biomarkers. The biomarkers described are reliably detected in stool and demonstrate significantly different expression levels in colorectal cancer patients when compared to colorectal cancer negative patients.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.2.2.1-4 | Award Amount: 15.40M | Year: 2013

Epilepsy is a major burden for patients and health systems worldwide. It is a common chronic neurological disorder affecting people of all ages, and the shortfall in existing treatments means that 30% of patients continue to suffer uncontrolled seizures. MicroRNAs (miRNA) are a recently-discovered, network-level layer of gene expression regulation that controls protein levels of entire signaling pathways. Research on miRNAs has unprecedented potential to (i) further our understanding of the underlying disease processes, (ii) deliver novel signatures and prognostic markers for response to therapy, and (iii) deliver novel therapeutics and drug targets. EpiMiRNA consortium members have pioneered discoveries on brain-specific miRNAs, established that miRNA changes are a feature of the pathophysiology of human temporal lobe epilepsy and have demonstrated experimentally that altering miRNA function can potently suppress epileptic seizures and seizure-damage. EpiMiRNA brings together experts on the neurobiology of miRNAs with the leading researchers working on miRNAs in epilepsy, epilepsy geneticists, leaders in miRNA-target detection, proteomics, and systems biology with research-intensive SMEs pursuing miRNA therapeutics and treatments for pharmacoresistant epilepsy. Through highly collaborative, inter-disciplinary and inter-sectorial research, EpiMiRNA will explain the mechanism by which miRNAs contribute to epileptogenesis, characterize genetic variation of miRNA in patients, evaluate seizure-suppressing effects of miRNAs in experimental models, identify novel miRNA modulatory molecules as potential future therapeutics, and develop miRNAs as prognostic markers to identify patients who respond to novel, non-pharmacological therapeutic interventions including brain stimulation. EpiMiRNA will generate the necessary critical mass in biomedical, clinical and industry/SME research to track, treat and prevent seizures and improve the clinical management of epilepsy patients.


Grant
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2013-1 | Award Amount: 1.52M | Year: 2013

MiRacle focuses on the development of a therapeutic formulation for the treatment of head and neck cancer. Head and neck cancer contributes to approximately 5% of all cancers in the Western world. Unfortunately the majority of H&N cancer patients present with advanced stages of disease. These patients frequently develop locoregional recurrences, distant metastasis and/or second primary tumors resulting in 5-years survival rates of less than 60% The development of novel anti-cancer agents to improve outcome is therefore urgently awaited. The goal of MiRacle is the advancement of a therapeutic tumor-killing miRNA formulation towards the clinic by combining two innovative technologies, i.e. therapeutic miRNA and head and neck tumor specific targeted drug delivery. Such a project requires (1) expertise in the therapeutic application of miRNA (InteRNA) and knowledge on the synthesis of biochemical active miRNA (Biospring), (2) expertise in a drug formulation to deliver the therapeutic miRNA into humans (Quiet) and understanding the synthesis of complex drug formulations (Octoplus), plus (3) in depth knowledge of the therapeutic indication, e.g. H&N cancer (VUmc) and skilfulness in toxicity tests that are required for RNA based drug registration (LPT). We believe that this project encompasses all parties that are required to successfully bring a tumor killing miRNA towards registration for first in human testing.


Gommans W.M.,InteRNA Technologies
Seminars in Cell and Developmental Biology | Year: 2012

An important epigenetic mechanism in mammals is adenosine deamination, which generates transcriptome variety through the conversion of single adenosines into inosines in RNA molecules. Inosine is interpreted as guanosine by the translational machinery, and when A-to-I RNA editing occurs in the coding region of pre-mRNA molecules this substitution can result in non-synonymous codon changes and subsequent altered protein function. Furthermore, editing can also take place in non-coding RNA molecules, including pri-miRNAs. In this review I intend to give an overview on the interplay between miRNA-mediated control of gene expression and RNA editing, and how editing could impact cellular behavior by influencing mature miRNA expression levels. © 2011 Elsevier Ltd.


The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.


The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.


The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.


Patent
InteRNA Technologies | Date: 2013-07-03

A diagnostic portfolio comprising or consisting of isolated nucleic acid molecules, their complement and/or fragments thereof, said nucleic acid molecules, complements, equivalents and/or fragments thereof being represented by sequences comprising or consisting of sequences having at least 80% of sequence identity with SEQ ID NO:1-92, or 49-140 or derived thereof (i.e. groups a), b), c), d), e), f), g), h), i) or j) or subgroups thereof) and their uses.


The invention relates to the therapeutic use of a combination in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.


The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).

Loading InteRNA Technologies collaborators
Loading InteRNA Technologies collaborators